Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study

Data from 16,505 patients followed over 4.9yrs suggests compared with non-nucleoside reverse transcriptase inhibitor use, integrase strand transfer inhibitor-based regimens were linked to increased risk of anaemia (HR 1.26, 95% CI 1.00-1.58) and severe anaemia (HR1.51, 1.07-2.11)

BMJ Open